Drug developer Novavax Inc said on Monday it has completed patient enrollment in the late-stage study of its COVID-19 vaccine in the United States and Mexico.
The company said last month its vaccine was 89.3 percent effective in preventing COVID-19 in a trial conducted in the United Kingdom and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK.
Novavax said it had enrolled 30,000 volunteers across the United States and Mexico.
In the late-stage trial, the company said 20 percent of participants were Latinx, 13 percent were African American, and 13 percent were 65 and older.
Novavax COVID vaccine highly effective, but not against South Africa variantUS biotech firm Novavax said Thursday its two-shot COVID-19 vaccine candidate showed 89.3 percent efficacy in a major Phase 3 clinical trial in ... Coronavirus
Coronavirus: Novavax delays US COVID-19 vaccine trial againVaccine maker Novavax said on Monday it has pushed back the start of a US-based, late-stage trial for its experimental COVID-19 vaccine and now ... Coronavirus
Coronavirus: Novavax delays US trial of COVID-19 vaccine candidate to NovemberNovavax on Tuesday delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, ... Coronavirus
Coronavirus: Novavax starts Phase 1 clinical trial of COVID-19 vaccine candidateNovavax said on Monday it has started the Phase 1 clinical trial of a novel coronavirus vaccine candidate and has enrolled the trial’s first ... Coronavirus